摘要
The efficient triggering of prodrug release has become a challengeable task for stimuli-responsive nanomedicine utilized in cancer therapy due to the subtle differences between normal and tumor tissues and heterogeneity. In this work, a dual ROS-responsive nanocarriers with the ability to self-regulate the ROS level was constructed, which could gradually respond to the endogenous ROS to achieve effective, hierarchical and specific drug release in cancer cells. In brief, DOX was conjugated with MSNs via thioketal bonds and loaded with beta-Lapachone. TPP modified chitosan was then coated to fabricate nanocarriers for mitochondria-specific delivery. The resultant nanocarriers respond to the endogenous ROS and release Lap specifically in cancer cells. Subsequently, the released Lap self-regulated the ROS level, resulting in the specific DOX release and mitochondrial damage in situ, enhancing synergistic oxidation-chemotherapy. The tumor inhibition Ratio was achieved to 78.49%. The multifunctional platform provides a novel remote drug delivery system in vivo.
学科与关键词
- A dual-amplified ROS-responsive nanosystem with self-accelerating drug release for synergistic chemotherapyLi, Jun; Zong, Qingyu; Zhao, Zhongyi; Yuan, Youyong*Chemical Communications, 2023, 59(21): 3142-3145.
- Reactive oxygen species-sensitive polymeric nanocarriers for synergistic cancer therapyCao, Ziyang; Li, Dongdong; Wang, Junxia; Yang, Xianzhu*Acta Biomaterialia, 2021, 130: 17-31.被引 41
- Self-immolative polyprodrug-based tumor-specific cascade amplificated drug release nanosystem for orchestrated synergistic cancer therapyWang, Kewei; Xiao, Xuan; Liu, Ye; Zong, Qingyu; Tu, Yalan; Yuan, Youyong*Biomaterials, 2022, 289: 121803.被引 5
